Pharmaceutical-Technology.com

Pharmaceutical-technology.com is part of a network of over 30 specialized B2B websites, reaching a vast global audience of active decision-makers, influencers, and thought leaders. Together, these platforms attract 55 million industry professionals each year. Being a part of GlobalData, we have access to an extensive database with over 1 billion data points that cover companies, deals, projects, forecasts, and trends. This wealth of information fuels our top-tier content. Our expertise spans more than 80 global markets and is supported by a dedicated team of over 800 award-winning journalists, researchers, and analysts, providing you with essential insights that can influence business outcomes. Our unique marketing solution combines award-winning targeting technology with our network of websites, offering a comprehensive approach that integrates insight, creativity, and advanced AI technology. This allows our clients to effectively identify, target, and engage with potential customers through access to our 30+ B2B media sites and their extensive sector-specific audiences. With unmatched reach, targeted data, and first-party data capabilities, we create outstanding campaigns for our clients. To learn more about our technology-driven marketing solution, please visit https://www.verdictmediastrategies.com/.

International, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#244929

United States

#138659

Health/Pharmacy

#274

Traffic sources

Monthly visitors

Articles

From discovery to delivery: making therapies reach patients faster

5 days ago | pharmaceutical-technology.com | Ross Law

David W Miller, CEO of Genesis Research Group, discusses how pharma's decade-long development approach is no longer fit for purpose. According to McKinsey research, first-time starters now account for approximately 40% of new FDA-approved assets but experience lower success rates than established organisations. Image credit: PeopleImages.com – Yuri A via Shutterstock.
Madrigal poised to enter European MASH market after CHMP endorsement

1 week ago | pharmaceutical-technology.com | Robert Barrie
FDA cell and gene therapy director exit increases ‘volatility’ for sector

1 week ago | pharmaceutical-technology.com | Robert Barrie

Nicole Verdun, a highly respected individual in the cell and gene therapy space, was placed on administrative leave this week. . The OTP is part of the Center for Biologics Evaluation and Research (CBER) and responsible for reviewing applications cell and gene therapy products. Image credit: Tada Images via Shutterstock.
UK and US governments pursue contrasting vaccine strategies

1 week ago | pharmaceutical-technology.com | Robert Barrie

While the UK’s Vaccine Innovation Pathway succeeds, the vaccine future in the US is destabilising. The UK’s Vaccine Innovation Pathway, the country’s first clinical trial accelerator, aims to expedite the research and development of vaccines. Credit: ZorroGabriel via Shutterstock. While the outlook for vaccines in the US looks bleak under the current administration, the UK Government is pressing ahead with securing its vaccine future.
BioOrbit eyes 2026 for pre-clinical trials of space manufactured protein crystals

1 week ago | pharmaceutical-technology.com | Abigail Beaney

CEO Dr Katie King said that the microgravity environment enables the production of purer crystals, resulting in more concentrated therapies. The ‘space factory’ will likely be within a satellite, King explained at HLTH Europe. Image credit: Rini. com/ Shutterstock. BioOrbit aims to kick off pre-clinical trials to study protein crystals for monoclonal antibodies (mAbs) produced in a pharmaceutical factory in space in 2026.
Eli Lilly and Eisai’s Alzheimer’s drugs denied NHS use due to high costs

1 week ago | pharmaceutical-technology.com | Robert Barrie

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value for money”. Both Kinsula and Leqembi are both approved by the Medicines and Healthcare products Regulatory Agency (MHRA), meaning they will still be available privately. AtlasStudio via Shutterstock.
NHS England chair suggests England can learn from European health schemes

1 week ago | pharmaceutical-technology.com | Abigail Beaney

Penny Dash shared her views during a fireside discussion at HLTH Europe in Amsterdam. NHS England chair Penny Dash speaking with The Sunday Times’ health editor Shaun Lintern. Image credit: Abigail Beaney / GlobalData. With the 10-year Health Plan on the horizon, the NHS could learn some tricks from France, Germany and the Nordics.
Bavarian Nordic nets $160m from priority review voucher sale

1 week ago | pharmaceutical-technology.com | Robert Barrie

Sale prices for the vouchers – which slash FDA review times for a drug – have increased in the past year as biotech funding dries up. Priority review vouchers are often bought by companies looking to dramatically reduce FDA review time for a new drug application. Credit: Jack_the_sparow via Shutterstock.
FDA Commissioner envisions fewer delays, more clinical trial flexibility and AI use

1 week ago | pharmaceutical-technology.com | Manasi Vaidya

At BIO 2025, FDA Commissioner Dr Marty Makary tried to allay industry concerns about recent cuts and outlined his agenda for the future. BIO President John Crowley [L] speaking to US FDA Commissioner Dr Marty Makary [R] at the BIO International Convention in Boston. Makary talked about his vision for the FDA, expedited programmes for drug review and the use of artificial intelligence (AI) tools.
Novo Nordisk seeks digital health partners to boost GLP-1RA weight loss outcomes

1 week ago | pharmaceutical-technology.com | Abigail Beaney

Novo Nordisk aims to collaborate with mobile app developers as well as pharmacies and telehealth providers. Anne Cathrine Fleischer, vice president of Global Obesity Consumer Engagement and New Business Models at Novo Nordisk, announced the platform at HLTH Europe.